Abstract 2672
Background
Vulvar cancer is a rare malignancy. Its occurrence in Japan is 1/6-1/10 of that in the Western countries. Population-based statisics for vulvar cancer has been missing in Japan. To examine trends in clinico-pathological characteristics of vulvar cancer in Japan.
Methods
This is a nationwide retrospective study examining consecutive cases of women with invasive vulvar cancer in Japan between 2001-2010 (n = 1,061). Temporal trends of demographics, tumor characteristics, and survival outcome were assessed with cohort-level analysis. The National Cancer Institute’s Surveillance, Epidemiology, and End Result Program served as the external validation (n = 10,154).
Results
The number of oldest-old women aged ≥80 years significantly increased from 18.0% to 30.6% (70.5% relative increase) over time. There was a stage-shift observed, and stage I disease decreased from 43.0% to 34.0% (21.0% relative decrease) whereas tumors with inguino-femoral nodal or distant metastasis increased from 23.2% to 35.6% (53.3% relative increase) during the study period (P < 0.05). The number of women who underwent surgical treatment decreased from 84.0% to 69.7% (17.0% relative decrease) whereas utilization of radiotherapy increased from 34.4% to 43.2% (25.7% relative increase) over time (P < 0.05). In the cohort-level analysis, the 5-year survival rates significantly decreased between 2001-2010 (P < 0.05): 66.9% to 51.0% for progression-free survival (23.7% relative decrease), 79.5% to 67.9% for cause-specific survival (14.6% relative decrease), and 74.9% to 62.3% for overall survival (16.9% relative decrease). In the patient-level analysis, oldest-old women were less likely to undergo surgical treatment and independently associated with decreased survival (all, P < 0.05). In the US cohort, the number of oldest-old women (25.2% to 27.8%) and the 5-year cause-specific survival rate (81.8% to 79.9%) stayed unchanged during the study period (all, P > 0.05).
Conclusions
Demographics and outcomes of vulvar cancer in Japan have significantly changed during the study period: Increasing oldest-old population and stage-shift to more metastatic disease resulted in cohort-level decrease in survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5489 - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy
Presenter: xijin lin
Session: Poster Display session 2
Resources:
Abstract
1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.
Presenter: Clémence Brun
Session: Poster Display session 2
Resources:
Abstract
5206 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
Presenter: Per Pfeiffer
Session: Poster Display session 2
Resources:
Abstract
2992 - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis
Presenter: Gerardo Rosati
Session: Poster Display session 2
Resources:
Abstract
4753 - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study
Presenter: Hong Jun Kim
Session: Poster Display session 2
Resources:
Abstract
2735 - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group
Presenter: Aimery De Gramont
Session: Poster Display session 2
Resources:
Abstract
1843 - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage Ⅲ Colon Cancer
Presenter: Ji Zhu
Session: Poster Display session 2
Resources:
Abstract
2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.
Presenter: Kaissa Ouali
Session: Poster Display session 2
Resources:
Abstract
3285 - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Presenter: Philip Falk
Session: Poster Display session 2
Resources:
Abstract
3905 - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer
Presenter: Krittiya Korphaisarn
Session: Poster Display session 2
Resources:
Abstract